Tags

Type your tag names separated by a space and hit enter

N1-Substituted benzimidazole scaffold for farnesoid X receptor (FXR) agonists accompanying prominent selectivity against vitamin D receptor (VDR).
Bioorg Med Chem. 2020 Jul 15; 28(14):115512.BM

Abstract

As a cellular bile acid sensor, farnesoid X receptor (FXR) participates in regulation of bile acid, lipid and glucose homeostasis, and liver protection. With respect to the bone metabolism, FXR positively regulates bone metabolism through both bone formation and resorption of the bone remodeling pathways. Some of FXR agonists possessing isoxazole moiety are undergoing clinical trials for the treatment of non-alcoholic steatohepatitis. To date, therefore, the activation of FXR leads to considerable interest in FXR as potential therapeutic targets. We have identified a series of nonsteroidal FXR agonists bearing N1-methyl benzimidazole and isoxazole moieties that are bridged with aromatic derivatives. They showed affinity to FXR, but also weak affinity toward the vitamin D receptor (VDR) that involves regulation of calcium and phosphate homeostasis and is activated by bile acids. The deployment of FXR agonists without activity against VDR as off-target is therefore crucial in the development of FXR ligands. Our efforts focusing on increasing the agonist properties towards FXR led to the discovery of 19, which activates FXR at and below nanomolar levels (EC50 = 26.5 ± 10.5 nM TR-FRET and 0.8 ± 0.2 nM luciferase, respectively) and functions as a FXR agonist: the affinity toward FXR over eight nuclear receptors, including VDR [IC50 (VDR) / EC50 (FXR) > 5000] and TGR5, effects FXR target genes, and activates bone morphogenetic protein-2-induced differentiation of mouse bone marrow-derived mesenchymal stem cell-like ST2 cells into osteoblast.

Authors+Show Affiliations

Graduate School of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hirokoshingai, Kure, Hiroshima 737-0112, Japan.Computer-aided Molecular Modeling Research Center, Kansai (CAMM-Kansai), 3-32-302, Tsuto-Otsuka, Nishinomiya 663-8241, Japan.Faculty of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hirokoshingai, Kure, Hiroshima 737-0112, Japan.Department of Pathobiochemistry, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan.Faculty of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hirokoshingai, Kure, Hiroshima 737-0112, Japan.Faculty of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hirokoshingai, Kure, Hiroshima 737-0112, Japan.Graduate School of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hirokoshingai, Kure, Hiroshima 737-0112, Japan; Faculty of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hirokoshingai, Kure, Hiroshima 737-0112, Japan.Graduate School of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hirokoshingai, Kure, Hiroshima 737-0112, Japan; Faculty of Clinical Nutrition, Hiroshima International University, 5-1-1 Hirokoshingai, Kure, Hiroshima 737-0112, Japan. Electronic address: n-teno@hirokoku-u.ac.jp.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32616182

Citation

Masuda, Arisa, et al. "N1-Substituted Benzimidazole Scaffold for Farnesoid X Receptor (FXR) Agonists Accompanying Prominent Selectivity Against Vitamin D Receptor (VDR)." Bioorganic & Medicinal Chemistry, vol. 28, no. 14, 2020, p. 115512.
Masuda A, Gohda K, Iguchi Y, et al. N1-Substituted benzimidazole scaffold for farnesoid X receptor (FXR) agonists accompanying prominent selectivity against vitamin D receptor (VDR). Bioorg Med Chem. 2020;28(14):115512.
Masuda, A., Gohda, K., Iguchi, Y., Fujimori, K., Yamashita, Y., Oda, K., Une, M., & Teno, N. (2020). N1-Substituted benzimidazole scaffold for farnesoid X receptor (FXR) agonists accompanying prominent selectivity against vitamin D receptor (VDR). Bioorganic & Medicinal Chemistry, 28(14), 115512. https://doi.org/10.1016/j.bmc.2020.115512
Masuda A, et al. N1-Substituted Benzimidazole Scaffold for Farnesoid X Receptor (FXR) Agonists Accompanying Prominent Selectivity Against Vitamin D Receptor (VDR). Bioorg Med Chem. 2020 Jul 15;28(14):115512. PubMed PMID: 32616182.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - N1-Substituted benzimidazole scaffold for farnesoid X receptor (FXR) agonists accompanying prominent selectivity against vitamin D receptor (VDR). AU - Masuda,Arisa, AU - Gohda,Keigo, AU - Iguchi,Yusuke, AU - Fujimori,Ko, AU - Yamashita,Yukiko, AU - Oda,Keisuke, AU - Une,Mizuho, AU - Teno,Naoki, Y1 - 2020/05/23/ PY - 2020/03/26/received PY - 2020/04/11/revised PY - 2020/04/13/accepted PY - 2020/7/4/entrez KW - Benzimidazole KW - FXR agonist KW - Osteoblast differentiation SP - 115512 EP - 115512 JF - Bioorganic & medicinal chemistry JO - Bioorg. Med. Chem. VL - 28 IS - 14 N2 - As a cellular bile acid sensor, farnesoid X receptor (FXR) participates in regulation of bile acid, lipid and glucose homeostasis, and liver protection. With respect to the bone metabolism, FXR positively regulates bone metabolism through both bone formation and resorption of the bone remodeling pathways. Some of FXR agonists possessing isoxazole moiety are undergoing clinical trials for the treatment of non-alcoholic steatohepatitis. To date, therefore, the activation of FXR leads to considerable interest in FXR as potential therapeutic targets. We have identified a series of nonsteroidal FXR agonists bearing N1-methyl benzimidazole and isoxazole moieties that are bridged with aromatic derivatives. They showed affinity to FXR, but also weak affinity toward the vitamin D receptor (VDR) that involves regulation of calcium and phosphate homeostasis and is activated by bile acids. The deployment of FXR agonists without activity against VDR as off-target is therefore crucial in the development of FXR ligands. Our efforts focusing on increasing the agonist properties towards FXR led to the discovery of 19, which activates FXR at and below nanomolar levels (EC50 = 26.5 ± 10.5 nM TR-FRET and 0.8 ± 0.2 nM luciferase, respectively) and functions as a FXR agonist: the affinity toward FXR over eight nuclear receptors, including VDR [IC50 (VDR) / EC50 (FXR) > 5000] and TGR5, effects FXR target genes, and activates bone morphogenetic protein-2-induced differentiation of mouse bone marrow-derived mesenchymal stem cell-like ST2 cells into osteoblast. SN - 1464-3391 UR - https://www.unboundmedicine.com/medline/citation/32616182/N1-Substituted_benzimidazole_scaffold_for_farnesoid X receptor_(FXR)_agonists_accompanying_prominent_selectivity_against_vitamin_D_receptor_(VDR) L2 - https://linkinghub.elsevier.com/retrieve/pii/S0968-0896(20)30338-2 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.